報價延遲最少15分鐘:2026/04/21 19:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
60.55 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.63/-4.44
|
|
企業價值
9.03B
|
| 資產負債 |
|
每股賬面淨值
18.66
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development. |
